Amazon ANNOUNCES Expanded Licensing Agreement and 4 Stocks Riding 52-Week Highs
Amerigroup Corp. (NYSE:AGP) stated that the antitrust waiting period for the closing of WellPoint’s (NYSE:WLP) $4.46 billion deal for the purchase of the company was lengthened following the Justice Department’s seeking of additional information from both companies, says Reuters. The waiting period was set to expire on August 22, and has now been lengthened by 30 days. The shares closed at $90.82, up $0.57 or 0.63% on the day. They have traded in a 52-week range of $37.57 to $90.41.
Amazon.Com (NASDAQ:AMZN) announced an expanded content licensing agreement with NBCUniversal Cable & New Media Distribution (NASDAQ:CMCSA), which will add hundreds of popular and award-winning TV episodes to Prime Instant Video, such as previous seasons of Parks and Recreation, Parenthood, Friday Night Lights, Heroes, Battlestar Galactica, and more. Prime Instant Video now has over 22,000 movies and TV episodes for Prime members to stream on Kindle Fire or any of the hundreds of compatible Amazon Instant Video devices like the iPad, Roku, Xbox 360 and the PlayStation 3. The shares closed at $245.74, up $4.54 or 1.88% on the day. They have traded in a 52-week range of $166.97 to $246.71.
Brookfield Asset Man (NYSE:BAM) mentions a Schedule 13D filing with the SEC made by Pershing Square referencing a letter sent by it to the Board of Directors of General Growth Properties, or GGP (NYSE:GGP). Brookfield stated: “Brookfield is not taking any steps to acquire GGP nor is it having any discussions with third parties in that regard. Brookfield has no interest in selling its stake in GGP. We are 100 percent supportive of the current management team of GGP and believe that GGP’s business plan has and will continue to create significant long term value for all stakeholders. When Brookfield was chosen as an investor in GGP, it was explicitly on the basis that we were a long term investor. We have invested considerable capital, time and attention to support management and the Board as they enhance the value of GGP for all concerned.” The current results are a testimony to their success. Withing the past 12 months, at the request of Pershing Square, Brookfield considered and discussed many possible transactions which would facilitate Pershing Square’s wish to increase the value of and create liquidity for its interest in GGP. These discussions have since ceased. Brookfield owns nearly 40 percent of GGP with a value of more than $8 billion. The shares closed at $35.41, up $0.19 or 0.54% on the day. They have traded in a 52-week range of $24.42 to $35.51.
Cbs Corp. (NYSE:CBS): TV broadcasters ease decades-old voluntary bans limiting their national alcohol advertising to beer and wine, according to the Wall Street Journal. This will allow them to begin a new stream of revenue as advertisers keep shifting their ad budgets to cable TV, the Internet,and online videos. It also notes that hard liquor has become more publicly accepted. The shares closed at $36.55, up $0.59 or 1.64% on the day. They have traded in a 52-week range of $17.99 to $36.43.
Eli Lilly And Compan (NYSE:LLY) announced that the primary endpoints, both cognitive and functional, were reached in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients suffering from mild-to-moderate Alzheimer’s disease, but a pre-specified secondary analysis of pooled data across both trials indicated statistically significant slowing of cognitive decline in the overall study population of patients suffering from mild-to-moderate Alzheimer’s disease. Furthermore, pre-specified secondary subgroup analyses of pooled data across both studies suggested a statistically significant slowing of cognitive decline in patients having mild Alzheimer’s disease, but not in patients having moderate Alzheimer’s disease. Adverse events with an incidence of a minimum of 1 percent that occurred statistically significantly more in the solanezumab group than in the placebo group were lethargy, rash. and malaise in EXPEDITION1 and angina in EXPEDITION2. A continuing, open-label extension study, EXPEDITION-EXT, is fully enrolled and should occur as planned. “We recognize that the solanezumab studies did not meet their primary endpoints, but we are encouraged by the pooled data that appear to show a slowing of cognitive decline,” stated John C. Lechleiter, Ph.D., chairman, president and CEO, Lilly. “We intend to discuss these data with regulatory authorities to gain their insights on potential next steps.” The shares closed at $43.86, up $1.46 or 3.44% on the day. They have traded in a 52-week range of $34.94 to $44.67.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.